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Activation of the human anaphase-promoting complex by
proteins of the CDC20/Fizzy family
Edgar R. Kramer*, Christian Gieffers*, Gabriele Hölzl†, Markus Hengstschläger†
and Jan-Michael Peters*
The initiation of anaphase and exit from mitosis depend
on the activation of the cyclosome/anaphase-
promoting complex (APC) that ubiquitinates regulatory
proteins such as anaphase inhibitors and mitotic cyclins
[1–4]. Genetic experiments have demonstrated that two
related WD40-repeat proteins — called Cdc20p and
Hct1p/Cdh1p in budding yeast and Fizzy and Fizzy-
related in Drosophila — are essential for APC-
dependent proteolysis [5–11]. Human orthologs of
these proteins — hCDC20/p55CDC [12] and hCDH1 —
have recently been found to associate with APC in a
cell-cycle-dependent manner [13,14]. Here, we show
that the amount of hCDC20 and hCDH1 bound to APC
correlates with a high ubiquitination activity of APC and
that binding of recombinant hCDC20 and hCDH1 can
activate APC in vitro. Our results suggest that the
association between hCDH1 and APC is regulated by
post-translational mechanisms, whereas the amount of
hCDC20 bound to APC may in addition be controlled by
hCDC20 synthesis and destruction [15]. The temporally
distinct association of hCDC20 and hCDH1 with APC
suggests that these proteins are, respectively, mitosis-
specific and G1-specific activating subunits of APC.
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Results and discussion
APC regulation during the human somatic cell cycle
To address whether APC activity is regulated by associa-
tion with hCDC20 or hCDH1, we enriched HeLa cells in
different cell-cycle phases by drug treatment and analyzed
the steady-state levels of hCDC20, hCDH1 and APC
(Figure 1a), the amounts of hCDC20 and hCDH1 bound
to APC (Figure 1b), and the specific cyclin B ubiquitina-
tion activity associated with APC (Figure 1c). As reported
recently [15], hCDC20 levels increased between G1 and
mitosis. Similar amounts of hCDH1 and the APC subunits
CDC27 and APC2 were detectable in all cell-cycle frac-
tions but the electrophoretic mobility of hCDC27,
hCDH1 and hCDC20 was decreased in mitotic cells
(Figure 1a). These mobility shifts could not be detected
after treatment with λ protein phosphatase, indicating that
these proteins are phosphorylated in mitosis.
Density gradient centrifugation and co-immunoprecipita-
tion experiments indicated that a fraction of hCDC20 and
hCDH1 is bound to APC (see the Supplementary material
published with this paper on the internet). In contrast to a
report [16] that Xenopus CDC20/Fizzy does not associate
with APC, our results agree with recent reports ([13,14]; W.
Zachariae and K. Nasmyth, personal communication) that
human and yeast CDC20 and CDH1 co-immunoprecipi-
tate with APC. The APC isolated from G1 cells contained
only small amounts of hCDC20, whereas increasingly larger
amounts co-immunoprecipitated from S-phase and mitotic
cells, respectively (Figure 1b). In contrast, similar amounts
of hCDH1 were bound to APC in G1 and S phases, and
hardly any hCDH1 was associated with APC in mitosis.
APC’s specific cyclin B ubiquitination activity was signifi-
cantly higher in mitosis and G1 than in S or G2 (Figure 1c),
demonstrating that APC activity is regulated in somatic cell
cycles, as is the case in embryonic cell cycles [2,3].
Some of the drugs used in the above experiments inter-
fere with APC regulation by activating the spindle check-
point ([13,14] and references therein). To analyze APC
regulation in the absence of cell-cycle inhibitors we there-
fore fractionated HeLa cells by centrifugal elutriation. As
in drug-arrested cells, the amount of hCDC20 associated
with APC increased between G1 and G2/M, whereas the
binding of hCDH1 to APC decreased between G1 and
G2/M, despite constant hCDH1 steady-state levels
(Figure 2a,b). In cyclin B ubiquitination assays, APC activ-
ity was maximal in G1 (Figure 2c and Supplementary
material). In both drug-arrested and elutriated cells the
amount of hCDC20 bound to APC therefore correlates
with hCDC20 steady-state levels, whereas the binding of
hCDH1 to APC is cell-cycle regulated. Importantly, these
data show that the activity of APC is high in mitosis and
G1 when large amounts of either hCDC20 or hCDH1 are
associated with APC.
hCDC20 and hCDH1 activate APC in vitro
To test whether the binding of hCDC20 and hCDH1 acti-
vates APC, we synthesized radiolabeled hCDC20 and
hCDH1 by transcription–translation reactions and tested
the ability of these proteins to bind to APC and to modu-
late its activity. As a control, we used the β subunit of
protein phosphatase 2A (PP2Aβ). Like hCDC20 and
hCDH1, PP2Aβ is a 55 kDa protein that contains seven
WD40 repeats (E. Ogris and A. Bauer, personal communi-
cation). A significant amount of hCDH1 and hCDC20
bound to immunoprecipitated APC, whereas only a small
amount of these proteins bound to antibody beads in the
absence of APC (Figure 3) or to pre-immune beads
(unpublished observation). PP2Aβ was only slightly
enriched on APC beads compared with control beads.
Similar amounts of hCDC20 associated with APC isolated
from  cells in logarithmic, G1 or S phase, but about three
times as much hCDC20 bound to mitotic APC (Figure 3).
A similar result was obtained for hCDH1, whereas the
small amount of PP2Aβ recovered on APC beads did not
vary in a cell-cycle-dependent manner. The binding of
hCDH1 to APC correlated with a significant increase in
APC’s cyclin B ubiquitination activity that was not
observed when APC was pre-incubated with reticulocyte
lysate alone (Figure 4a,b). Also, the binding of hCDC20 to
APC correlated with an increase in APC activity, but this
effect was significantly smaller. PP2Aβ had no effect on
APC activity. hCDH1 could also bind to Xenopus APC, the
activity of which was thereby dramatically increased
(Figure 4c,d). In dose–response experiments, APC activity
correlated with the amount of associated hCDH1 (Supple-
mentary material), implying that the binding of hCDH1
and the stimulation of APC activity are causally related.
How do hCDC20 and hCDH1 activate APC-dependent
proteolysis?
Our results, and similar experiments that were published by
Fang et al. [17] after submission of this manuscript, suggest
that the amounts of hCDC20 and hCDH1 bound to APC
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APC regulation in drug-arrested HeLa cells. (a) Extracts of
logarithmically growing cells (log) and cells enriched either in G1 with
lovastatin (lova), in S with hydroxyurea (HU) or in mitosis with
colcemid (col) were analyzed by immunoblotting with antibodies
specific to the proteins indicated on the left. In addition, lysates from
colcemid-arrested cells were either incubated with λ protein
phosphatase (col + PPase) or with control buffer (col – PPase) for
30 min at 30°C before immunoblot analysis. Equal amounts of
proteins were analyzed in each lane. Anti-proteasome antibodies
were used as a loading control. (b) APC immunoprecipitates (IPs)
were analyzed by immunoblotting as in (a). (c) Time course of
ubiquitination of 125I-labeled cyclin B 13–110 by APC
immunoprecipitates in a reconstituted system. Nitrogen mustard (NM)
was used to enrich cells in G2.
Figure 2
APC regulation in elutriated HeLa cells. (a) Immunoblot analysis of
lysates from elutriated cells. (b) APC immunoprecipitates obtained
were analyzed by immunoblotting as in (a). (c) Time course of
ubiquitination of 125I-labeled cyclin B 13–110 by APC
immunoprecipitates in a reconstituted system.
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are rate-limiting for ubiquitination reactions. We do not
know, though, whether hCDC20 and hCDH1 participate
directly in substrate ubiquitination or allosterically activate
other APC components. In this respect it is worth noting
that hCDC20 and hCDH1 contain WD40 repeats, as do
several substrate-recognition factors of the SCF ubiquitina-
tion complex [4]. It is therefore conceivable that hCDC20
and hCDH1 function by recruiting specific substrates to
APC, a hypothesis that could explain why Cdc20p and
Hct1p/Cdh1p confer substrate specificity to APC-depen-
dent proteolysis in yeast [7,9,11]. It will be interesting to
test whether hCDC20 and hCDH1 bind APC substrates in
a specific manner. Our observation that both hCDC20 and
hCDH1 could stimulate cyclin B ubiquitination in vitro
does not rule out the possibility that hCDC20 and hCDH1
display specificity towards other APC substrates. 
How are hCDC20 and hCDH1 regulated?
Unlike previously identified APC subunits, hCDC20 and
hCDH1 bind to APC preferentially during mitosis and G1,
respectively, suggesting that hCDC20 is required for
mitotic APC activity and hCDH1 may maintain APC activ-
ity in G1. This interpretation agrees well with the observa-
tion that the expression of Drosophila and Xenopus
CDH1/Fizzy-related is restricted to cell cycles that include
a G1 phase, in contrast to the expression of CDC20/Fizzy,
which is essential for mitosis in embryonic cell cycles [8,16].
Although our results are consistent with the view that
binding of hCDC20 to APC is limited by the cellular levels
of hCDC20, additional mechanisms may regulate the asso-
ciation between hCDC20 and APC. The latter possibility
is suggested by our observation that only a fraction of
hCDC20 is associated with APC (Supplementary material)
and by the finding that mitotic APC binds more 
recombinant hCDC20 than APC from other cell-cycle
phases (Figure 3). Mitotic phosphorylation of APC or
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Figure 3
In vitro translated hCDC20 and hCDH1 bind
to APC from HeLa cells. APC
immunoprecipitates were incubated with
reticulocyte lysates containing in vitro
translated (IVT) hCDC20, hCDH1 or PP2Aβ,
which were labeled with [35S]methionine and
[35S]cysteine. As a specificity control, CDC27
antibody beads were used without bound
APC. Subsequently, the immunoprecipitates
were washed in buffers containing 0.5 M KCl
and 5% NP40 and analyzed by SDS–PAGE
and phosphorimaging. The amount of APC in
each immunoprecipitate was determined by
quantitative immunoblotting with APC2
antibodies and 125I-labeled secondary
antibodies. The intensities of the in vitro
translated proteins are not directly
comparable because hCDC20, hCDH1 and
PP2Aβ contain 14, 13 and 19 35S-labeled
residues, respectively.
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Figure 4
hCDC20 and hCDH1 activate APC in vitro. APC immunoprecipitates
from logarithmic HeLa cells (log) or from Xenopus interphase extracts
(xti) were incubated with reticulocyte lysates containing either
hCDC20, hCDH1, PP2Aβ, or no translation product (+RRL).
Subsequently, the immunoprecipitates were washed and used in
ubiquitination assays. Samples were taken at 0, 5, 15 and 30 min and
analyzed by SDS–PAGE and phosphorimaging (a,c), and activities
were quantitated (b,d). The in vitro translated proteins associated with
APC are marked by asterisks.
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hCDC20 may therefore increase their association, a possibil-
ity that could explain the previously observed requirement
for phosphorylation in mitotic APC activation [3,18–20].
Our results indicate that the binding of hCDH1 to APC is
inhibited in mitosis. It is unlikely that mitotic APC phos-
phorylation prevents hCDH1 binding because recombi-
nant hCDH1 associated well with mitotic APC (Figure 3);
however, hCDH1 is also subject to phosphorylation in vivo
(Figure 1a), and it will therefore be interesting to test
whether this modification results in dissociation of
hCDH1 from APC. Phosphorylation of hCDH1 may also
prevent hCDH1 binding in S and G2, where less hCDH1
is associated with APC. This hypothesis could explain
why mitotic as well as G1-specific kinases inhibit
Hct1p/Cdh1p-dependent proteolysis in yeast [21] and
why cyclin E/CDK2 negatively regulates degradation of
mitotic cyclins in Drosophila [8].
In summary, our results suggest that hCDC20 and
hCDH1 are rate-limiting activating subunits of APC in
mitosis and G1, respectively. The amount of hCDC20
bound to APC is limited by the cellular steady-state levels
of hCDC20, but efficient binding in mitosis may further
require mitotic phosphorylation of APC or hCDC20.
hCDH1 is present at constant levels throughout the cell
cycle but appears to associate with APC only from the end
of mitosis or the beginning of G1. The binding of hCDH1
to APC is decreased in S and G2 phase and completely
inhibited in early mitosis, perhaps by phosphorylation of
hCDH1. These results indicate that the binding of
hCDC20 and hCDH1 to APC is a regulated process that
controls APC activity during the cell cycle.
Supplementary material
Additional methodological detail and three additional figures are pub-
lished with this article on the internet.
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Materials and methods
cDNAs and recombinant protein expression
Sequence analysis revealed that the human expressed sequence tag
clones 577261 and 124782 (nomenclature of the American Type
Culture Collection (ATCC)) represent overlapping 5′ and 3′ fragments
of a human cDNA highly related to Xenopus fizzy-related and budding
yeast HCT1/CDH1 [S1–S3]. A complete hCDH1 cDNA (pHCDH1-
BS) was constructed by cloning the non-overlapping parts of both frag-
ments into pBluescript (Stratagene). This cDNA encodes a protein of
493 amino acid residues with a predicted molecular mass of 55 kDa.
Sequence analysis showed that the ATCC clone number 551326 con-
tains a human cDNA encoding a protein identical to p55CDC [S4] except
for amino acid residue 101 which is a serine in p55CDC but a proline in
our sequence. We refer to this cDNA as hCDC20. The National Center
for Biotechnology Information (NCBI) accession number for hCDC20 is
AF099644. Xenopus fizzy-related [S1] and rat PP2Aβ cDNAs [S5]
were kindly provided by C. Lehner and E. Ogris, respectively.
[35S]methionine-labeled and [35S]cysteine-labeled proteins were pre-
pared by coupled transcription–translation reactions in rabbit reticulo-
cyte lysate (Promega). Bacterially synthesized hCDH1 and hCDC20
were generated by cloning the respective cDNAs into pET-28 vectors
(Novagene). Proteins containing an amino-terminal hexahistidine tag
were expressed in Escherichia coli BL21(DE)pLysS cells (Novagene)
and purified on Ni–NTA agarose (Qiagen).
Antibodies
Antibodies to human cyclins A, B and E and hCDC20 (carboxy-terminal
peptide) were from Santa Cruz. Additional hCDC20 antibodies were
raised against bacterially synthesized protein in rabbits. Antibodies
against hCDH1 were generated by immunizing rabbits with the syn-
thetic peptide MDQDYERRLLRQINLQNEC (amino terminus of
Xenopus Fizzy-related) coupled to keyhole limpet hemocyanin. In
immunoblotting experiments, the resulting hCDH1 antisera recognized
bacterially expressed hCDH1, in vitro translated hCDH1 and Xenopus
Fizzy-related and a 55 kDa band in HeLa extracts. No crossreaction
was observed in immunoblotting experiments between hCDH1 anti-
bodies and hCDC20 protein, or between hCDC20 antibodies and
hCDH1 protein. APC and PLK1 antibodies were generated by immu-
nizing rabbits with recombinant proteins. Monoclonal anti-proteasome
antibodies have been described [S6].
Cell culture and cell synchronization
Adherent HeLa cells were grown at 37°C and in the presence of 5% CO2
in DMEM supplemented with 10% fetal bovine serum, 0.3µg/ml L-gluta-
mine, 100 units/ml penicillin and 100µg/ml streptomycin. To induce cell-
cycle arrests, cells were grown to 50% confluency and subsequently
cultured for 17–18 h in the presence of 330 nM nocodazole (Sigma),
190 nM colcemid (Sigma), 50 µM activated lovastatin (Merck Sharp and
Dohme), 2 mM hydroxyurea (Sigma), 400µM mimosine (Aldrich) or 10µM
nitrogen mustard (Sigma). Lovastatin was activated as described [S7].
Separation of logarithmically growing cells into distinct cell-cycle phases
was accomplished by centrifugal elutriation which was performed as
described [S8], using a Beckman J2–21 M centrifuge equipped with a
JE–6B rotor and a standard separation chamber. The rotor was kept at
a speed of 2000 rpm and a temperature of 20°C, and medium flow was
controlled with a Cole-Parmer Masterflex pump. Typically, 8× 108 cells
were fractionated, and consecutive fractions of 150 ml were collected
at increasing flow rates. Cytofluorometric analyses were performed
using a Becton–Dickinson FACScan. DNA was stained with propidium
iodide (Sigma).
Preparation of cell extracts and protein fractionation
HeLa cells arrested with drugs were scraped from the plates and washed
with ice-cold PBS (140 mM NaCl, 6.4 mM Na2HPO4, 2.6 mM KCl,
1.4 mM KH2PO4, pH 7.4). Elutriated cell fractions were also washed with
PBS before lysis. Protein extracts were prepared in buffer containing
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 10% glycerol, 2 mM
EDTA, pH 8.0, 50 mM NaF, 0.25 mM Na3VO4, 1 mM PMSF, 1 mM DTT,
1 µM okadaic acid (Calbiochem), and 10 µg/ml each of chymostatin, leu-
peptin, and pepstatin (Sigma). After 20 min on ice with occasional dounc-
ing or pipetting, the lysates were centrifuged at 14,000 rpm in an
Eppendorf centrifuge, shock frozen in liquid nitrogen and stored at –70°C.
Xenopus interphase egg extracts were prepared as described [S9].
For sucrose density gradient centrifugation, 10–40% sucrose gradi-
ents loaded with cell extracts containing 2–3 mg protein were cen-
trifuged for 18 h at 30,000 rpm in an SW40 rotor (Beckman) at 4°C.
Gradients were prepared with a Biocom gradient master and fractions
were collected with a density gradient fractionator (ISCO).
Immunoprecipitation and immunoblotting experiments
For the immunoblot analysis of immunoprecipitates, CDC27 antibodies
were coupled to protein A-Affiprep beads (Bio-Rad) for 2 h at 4°C and
crosslinked with dimethylpimilimidate as described [S10]. CDC27 anti-
body beads (20 µl) were incubated with 4–5 mg protein diluted in IP
buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM β-glycerophos-
phate, 5% glycerol, 0.01% NP-40, 0.5 mM DDT, proteinase inhibitors
[‘complete mixture’, Boehringer]) for 2 h at 4°C. Subsequently, the
beads were washed four times with immunoprecipitation buffer and
bound proteins were eluted with 100 mM glycine-HCl pH 2.0 and ana-
lyzed by SDS–PAGE and immunoblotting using PVDF membrane.
Immunoreactions were detected using the enhanced chemilumines-
cence system (Amersham).
In vitro binding assays
To analyze the binding of in vitro translated proteins to the APC, 6 µl
CDC27 antibody beads were washed with QA buffer (10 mM Tris-HCl
pH 7.5, 100 mM KCl, 1 mM MgCl2, 0.1 mM CaCl2, 1 mM DTT) and
incubated either with HeLa cell extract containing 3 mg protein or with
QA buffer for 2 h at 4°C. Beads were washed once with 200 volumes
QA, once with QA containing additional 400 mM KCl and 5% NP-40,
and three times with QA. In vitro translation mixtures were added to the
APC beads and incubated for 30 min at 37°C. The APC beads were
then washed five times as above and bound proteins were eluted with
SDS sample buffer, separated by SDS–PAGE and analyzed by phos-
phorimaging or immunoblotting using 125I-labeled secondary antibod-
ies. Radiolabeled gels were analyzed on a phosphorimager and
quantitated using the ImageQuant program (Molecular Dynamics).
In vitro ubiquitination assays
To measure APC activity, 6 µl CDC27 antibody beads were washed
with QA buffer and incubated either with HeLa cell extract containing
3 mg protein or with Xenopus egg extract containing 1 mg protein for
2 h at 4°C. Subsequently, the beads were washed as described for the
Supplementary material
in vitro binding assays. Where indicated, APC beads were pre-incu-
bated with in vitro translation mixtures for 30 min, either at 37°C in the
case of HeLa APC or at room temperature in the case of Xenopus
APC. The APC beads were then washed again five times as above.
Ubiquitination assays were performed in a volume of 10 µl, containing
6 µl beads and 4 µl reaction mix (80 µg/ml bacterially expressed and
purified wheat E1, 50 µg/ml each of Xenopus UBC4 and UBCx,
1.25 mg/ml ubiquitin, 30 units/ml rabbit creatine phosphokinase type I
(Sigma), 7.5 mM creatine phosphate, 1 mM ATP, 1 mM MgCl2, 0.1 mM
EGTA, and 3 µg/ml iodinated sea-urchin cyclin B fragment (amino
acids 13–110) as a substrate). Reaction mixtures containing HeLa cell
APC were incubated in an Eppendorf thermomixer at 37°C; mixtures
containing Xenopus APC were incubated at room temperature.
Samples were analyzed by 5–15% SDS–PAGE, phosphorimaging and
quantitation as described above. 
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Figure S1
Association of hCDC20 and hCDH1 with APC. 
(a) Co-immunoprecipitation of APC subunits and hCDC20. Extracts
from logarithmically growing cells were precipitated with antibodies
either against hCDC20 (CDC20-IP) or against CDC27 (CDC27-IP)
and the immunoprecipitates were analyzed by immunoblotting against
APC2 and hCDC20. Note that much less hCDC20 coprecipitates
with CDC27 than with hCDC20 antibodies, suggesting that only a
small fraction of APC complexes are associated with hCDC20.
(b) Cosedimentation of hCDH1 and hCDC20 with APC during
sucrose density gradient centrifugation. Extracts from logarithmically
growing cells were fractionated on a 10–40% sucrose gradient.
Subsequently, each fraction was analyzed by immunoblotting with
antibodies to the indicated proteins. The centrifugation was performed
under conditions that destabilize the 26S proteasome holo-complex
(see [S6]). Therefore, the proteasome antibodies detect only the 20S
core complex of the 26S proteasome.
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Figure S2
Regulation of APC’s cyclin B ubiquitination
activity in elutriated HeLa cells. (a) Analysis of
the cellular DNA content of elutriated cells by
flow cytometry. (b,c) Time courses showing
the ability of APC immunoprecipitates from
elutriated cells to ubiquitinate 125I-labeled
cyclin B (CycB) in a reconstituted system.
Samples were analyzed by SDS–PAGE and
phosphorimaging (c), and the ubiquitination
activities were expressed as the percentage
of cyclin B converted into conjugates (b).
(d) Quantitative immunoblot analysis of the
immunoprecipitates used in (b,c) with APC2
antibodies and 125I-labeled secondary
antibodies. Immunoreactions were detected
by phosphorimaging. Quantitation of the
immunoreactions showed that the amounts of
APC detected in each immunoprecipitate
varied by less than 10% (data not shown).
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Figure S3
Dose-dependent activation of APC’s cyclin B
ubiquitination activity by in vitro translated
hCDH1. (a,b) Time courses showing the
ability of APC immunoprecipitates associated
with different amounts of hCDH1 to
ubiquitinate 125I-labeled cyclin B (CycB) in a
reconstituted system. APC was isolated from
logarithmically growing HeLa cells (log) and
incubated with different volumes of
reticulocyte lysates containing either in vitro
translated hCDH1 (+hCDH1), or no
translation product (+RRL). Subsequently, the
immunoprecipitates were re-isolated, washed
and used in ubiquitination assays. Samples
were analyzed by SDS–PAGE and
phosphorimaging (b), and the ubiquitination
activities were expressed as the percentage
of cyclin B converted into conjugates (a). In
vitro translated hCDH1 associated with the
APC is marked by asterisks. (c) Quantitation
of the different amounts of in vitro translated
hCDH1 associated with APC.
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